脂代谢对主动脉疾病发生发展及预后的影响

王宇航; 沈振亚

doi:10.16766/j.cnki.issn.1674-4152.003126

脂代谢对主动脉疾病发生发展及预后的影响

doi: 10.16766/j.cnki.issn.1674-4152.003126

王宇航,
沈振亚^,

苏州大学附属第一医院心脏大血管外科，江苏苏州 215006

基金项目:

国家自然科学基金项目 91839101

详细信息

通讯作者:
沈振亚, E-mail: uuzyshen@aliyun.com

中图分类号: R543.1 R589.2
计量
- 文章访问数: 109
- HTML全文浏览量: 60
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2023-02-23
- 网络出版日期: 2023-09-13

The effect of lipid metabolism on the occurrence, development and prognosis of aortic disease

WANG Yuhang,
SHEN Zhenya^,

Department of Cardiovascular Surgery, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China

摘要

摘要: 以主动脉瘤和主动脉夹层为代表的主动脉疾病作为一类高发病率和高死亡率的疾病受到广泛重视，其缺乏有效的早期预警标志，同时，手术治疗死亡率也较高。主动脉疾病的发病机制尚未完全明确。目前，主动脉疾病已被证实与高血压、动脉粥样硬化、性别、遗传变异、炎症等各种改变主动脉壁受力的因素相关。随着经济社会的发展，以高脂血症为代表的血脂代谢异常在世界范围内的发病率日益增加。血脂异常增加动脉粥样硬化和血管功能障碍的风险，并最终导致冠心病、脑卒中等各类心脑血管疾病的发生。目前发现高脂血症对主动脉疾病的发生发展存在不良影响，更好地了解脂代谢紊乱和主动脉疾病之间的关系有助于临床上对主动脉疾病的预防和诊治。同时，各种调脂药物可以通过不同脂质代谢位点对血脂进行有效控制，调脂药物已在各类心脑血管疾病的预防和临床治疗中起到重要作用。控制血脂和改善动脉粥样硬化对主动脉疾病的发生有较好的预防效果。本文总结了近年关于临床血脂指标、高脂血症与主动脉疾病的发生、发展和预后之间的关系，并探讨脂代谢紊乱及调脂药物对主动脉疾病影响的细胞和分子通路以及其潜在应用前景。
- 主动脉疾病 /
- 脂代谢 /
- 高脂血症 /
- 调脂药物 /
- 发病机制
Abstract: Aortic diseases, such as aortic aneurysm and aortic dissection, have attracted wide attention as a kind of diseases with high morbidity and high mortality, which lack effective early warning markers and have a high mortality after surgical treatment. The pathogenesis of aortic disease is not fully understood. At present, aortic disease has been proven to be associated with hypertension, atherosclerosis, gender, genetic variation, inflammation and other factors that change the force on the aortic wall. With the development of economy and society, the incidence of dyslipidemia represented by hyperlipidemia is increasing in the world. Dyslipidemia increases the risk of atherosclerosis and vascular dysfunction, and ultimately leads to coronary heart disease, stroke and other cardiovascular and cerebrovascular diseases. Currently, hyperlipidemia has been found to have adverse effects on the occurrence and development of aortic diseases. A better understanding of the relationship between lipid metabolism disorders and aortic diseases is helpful for clinical prevention, diagnosis and treatment of aortic diseases. At the same time, various lipid-regulating drugs can effectively control blood lipid through different lipid metabolic sites, and lipid-regulating drugs have played an important role in the prevention and clinical treatment of various cardiovascular and cerebrovascular diseases. Controlling blood lipids and improving atherosclerosis have better preventive effect on the occurrence of aortic diseases. This paper summarizes the relationship between clinical lipid indexes, hyperlipidemia and the occurrence, development and prognosis of aortic diseases in recent years, and probes into the cellular and molecular pathways of lipid metabolism disorders and the effects of lipid-regulating drugs on aortic diseases, as well as their potential application prospects.
- Aortic disease /
- Lipid metabolism /
- Hyperlipidemia /
- Lipid-regulating drug /
- Pathogenesis

HTML全文

参考文献(43)

[1]	TANG X, LU K, LIU X, et al. Incidence and survival of aortic dissection in urban china: results from the national insurance claims for epidemiological research (nicer) study[J]. Lancet Reg Health West Pac, 2021, 17: 100280. DOI: 10.1016/j.lanwpc.2021.100280.
[2]	SAYED A, MUNIR M, BAHBAH E I. Aortic dissection: a review of the pathophysiology, management and prospective advances[J]. Curr Cardiol Rev, 2021, 17(4): e230421186875. DOI: 10.2174/1573403x16666201014142930.
[3]	GURUNG R, CHOONG A M, WOO C C, et al. Genetic and epigenetic mechanisms underlying vascular smooth muscle cell phenotypic modulation in abdominal aortic aneurysm[J]. Int J Mol Sci, 2020, 21(17). DOI: 10.3390/ijms21176334.
[4]	PAGHDAR S, KHAN T M, PATEL N P, et al. Doxycycline therapy for abdominal aortic aneurysm: inhibitory effect on matrix metalloproteinases[J]. Cureus, 2021, 13(5): e14966. DOI: 10.7759/cureus.14966.
[5]	PRADO A F, BATISTA R I M, TANUS-SANTOS J E, et al. Matrix metalloproteinases and arterial hypertension: role of oxidative stress and nitric oxide in vascular functional and structural alterations[J]. Biomolecules, 2021, 11(4). DOI: 10.3390/biom11040585.
[6]	LIBBY P. The changing landscape of atherosclerosis[J]. Nature, 2021, 592(7855): 524-533. doi: 10.1038/s41586-021-03392-8
[7]	ZHANG F, GUO X, XIA Y, et al. An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis[J]. Cell Mol Life Sci, 2021, 79(1): 6.
[8]	LIU X, LIU J, LI Y, et al. The correlation between the inflammatory effects of activated macrophages in atherosclerosis and aortic dissection[J]. Ann Vasc Surg, 2022, 85: 341-346. doi: 10.1016/j.avsg.2022.03.027
[9]	NANA P, DAKIS K, BRODIS A, et al. Circulating biomarkers for the prediction of abdominal aortic aneurysm growth[J]. J Clin Med, 2021, 10(8). DOI: 10.3390/jcm10081718.
[10]	MIAO J, ZANG X, CUI X, et al. Autophagy, hyperlipidemia, and atherosclerosis[J]. Adv Exp Med Biol, 2020, 1207: 237-264. DOI: 10.1007/978-981-15-4272-5_18.
[11]	CHEN Y, HUANG M, XUAN Y, et al. Association between lipid levels and risk for different types of aneurysms: a mendelian randomization study[J]. J Pers Med, 2021, 11(11). DOI: 10.3390/jpm11111171.
[12]	RODRÍGUEZ-CARRIO J, CERRO-PARDO I, LINDHOLT J S, et al. Malondialdehyde-modified hdl particles elicit a specific igg response in abdominal aortic aneurysm[J]. Free Radic Biol Med, 2021, 174: 171-181. doi: 10.1016/j.freeradbiomed.2021.08.004
[13]	VAN DER VORST E P C. High-density lipoproteins and apolipoprotein a1[J]. Subcell Biochem, 2020, 94: 399-420.
[14]	LIN Y J, LIN J L, PENG Y C, et al. TG/HDL-C ratio predicts in-hospital mortality in patients with acute type a aortic dissection[J]. BMC Cardiovasc Disord, 2022, 22(1): 346. doi: 10.1186/s12872-022-02793-5
[15]	FATTAHI N, ROSENBLAD A, KRAGSTERMAN B, et al. Risk factors in 50-year-old men predicting development of abdominal aortic aneurysm[J]. J Vasc Surg, 2020, 72(4): 1337-1346.e1331. DOI: 10.1016/j.jvs.2019.11.062.
[16]	LEE J S, PARK S C, KIM S D. Effects of hypercholesterolism on expansion of abdominal aortic aneurysm in rat model[J]. J Cardiothorac Surg, 2021, 16(1): 352. doi: 10.1186/s13019-021-01734-1
[17]	LIU X, SU X, ZENG H. Impact of admission serum total cholesterol level on in-hospital mortality in patients with acute aortic dissection[J]. Pak J Med Sci, 2016, 32(4): 939-943.
[18]	ZENG X, ZHOU X, TAN X R, et al. Admission ldl-c and long-term mortality in patients with acute aortic dissection: a survival analysis in china[J]. Ann Transl Med, 2021, 9(16): 1345. doi: 10.21037/atm-21-3511
[19]	WANG B, LIU J, CHEN S, et al. Malnutrition affects cholesterol paradox in coronary artery disease: a 41, 229 chinese cohort study[J]. Lipids Health Dis, 2021, 20(1): 36. doi: 10.1186/s12944-021-01460-6
[20]	IBRAHIM M, THANIGAIMANI S, SINGH T P, et al. Systematic review and meta-analysis of mendelian randomisation analyses of abdominal aortic aneurysms[J]. Int J Cardiol Heart Vasc, 2021, 35: 100836. DOI: 10.1016/j.ijcha.2021.100836.
[21]	TANG W, YAO L, ROETKER N S, et al. Lifetime risk and risk factors for abdominal aortic aneurysm in a 24-year prospective study: the aric study (atherosclerosis risk in communities)[J]. Arterioscler Thromb Vasc Biol, 2016, 36(12): 2468-2477. doi: 10.1161/ATVBAHA.116.308147
[22]	LIU X T, HE X W, TAN R, et al. High-density lipoprotein cholesterol and in-hospital mortality in patients with acute aortic dissection[J]. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(3): 364-367. doi: 10.1007/s11596-016-1592-9
[23]	ZHOU Y, YANG G, HE H, et al. Triglyceride/high-density lipoprotein cholesterol ratio is associated with in-hospital mortality in acute type b aortic dissection[J]. Biomed Res Int, 2020, 2020: 5419846. DOI: 10.1155/2020/5419846.
[24]	LI T, YANG C, YANG J, et al. Elevated triglyceride-glucose index predicts mortality following endovascular abdominal aortic aneurysm repair[J]. Front Nutr, 2023, 10: 1116425. DOI: 10.3389/fnut.2023.1116425.
[25]	HEIDEMANN B E, KOOPAL C, BOTS M L, et al. The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease[J]. Int J Cardiol, 2021, 322: 251-257. doi: 10.1016/j.ijcard.2020.08.030
[26]	ALLARA E, MORANI G, CARTER P, et al. Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled mendelian randomization investigation[J]. Circ Genom Precis Med, 2019, 12(12): e002711. DOI: 10.1161/circgen.119.002711.
[27]	ERHART P, KÖRFER D, GROND-GINSBACH C, et al. Genetic variation in lrp1 associates with stanford type B aortic dissection risk and clinical outcome[J]. J Cardiovasc Dev Dis, 2022, 9(1). DOI: 10.3390/jcdd9010014.
[28]	LEGAKI E, SIASOS G, KLONARIS C, et al. Mir-335-5p as a potential regulator of lrp1 expression in abdominal aortic aneurysm[J]. Hellenic J Cardiol, 2020, 61(6): 430-432. doi: 10.1016/j.hjc.2020.01.002
[29]	XIE N, ZHANG W, LI H, et al. Admission values of plasma biomarkers predict the short-term outcomes in acute aortic dissection[J]. Heart Surg Forum, 2021, 24(1): e048-e054. doi: 10.1532/hsf.3417
[30]	HENEIN M Y, VANCHERI S, LONGO G, et al. The role of inflammation in cardiovascular disease[J]. Int J Mol Sci, 2022, 23(21). DOI: 10.3390/ijms232112906.
[31]	PARASKEVAS K I, MUKHERJEE D, LIAPIS C D, et al. Statin use and cardiovascular event/death rates after abdominal aortic aneurysm repair procedures[J]. Curr Vasc Pharmacol, 2022, 20(4): 313-314. doi: 10.2174/1570161119666210930100154
[32]	XIONG X, WU Z, QIN X, et al. Meta-analysis suggests statins reduce mortality after abdominal aortic aneurysm repair[J]. J Vasc Surg, 2022, 75(1): 356-362.e354. DOI: 10.1016/j.jvs.2021.06.033.
[33]	FORSDAHL S H, SINGH K, SOLBERG S, et al. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the tromsø study, 1994-2001[J]. Circulation, 2009, 119(16): 2202-2208. doi: 10.1161/CIRCULATIONAHA.108.817619
[34]	GUO Y, YAN B, GUI Y, et al. Physiology and role of pcsk9 in vascular disease: potential impact of localized pcsk9 in vascular wall[J]. J Cell Physiol, 2021, 236(4): 2333-2351. doi: 10.1002/jcp.30025
[35]	PASTA A, CREMONINI A L, PISCIOTTA L, et al. Pcsk9 inhibitors for treating hypercholesterolemia[J]. Expert Opin Pharmacother, 2020, 21(3): 353-363. doi: 10.1080/14656566.2019.1702970
[36]	TANAKA H, IIDA Y, IWAKI T, et al. Elevated plasma levels of ldl cholesterol promote dissecting thoracic aortic aneurysms in angiotensin ii-induced mice[J]. Ann Vasc Surg, 2018, 48: 204-213. doi: 10.1016/j.avsg.2017.10.006
[37]	LIU C, CHEN J, CHEN H, et al. Pcsk9 inhibition: from current advances to evolving future[J]. Cells, 2022, 11(19). DOI: 10.3390/cells11192972.
[38]	SCHMIDT A F, SWERDLOW D I, HOLMES M V, et al. Pcsk9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study[J]. Lancet Diabetes Endocrinol, 2017, 5(2): 97-105. doi: 10.1016/S2213-8587(16)30396-5
[39]	BANERJEE S, DE A. Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: an update[J]. Drug Discov Today, 2021, 26(7): 1759-1764. doi: 10.1016/j.drudis.2021.03.016
[40]	ADORNI M P, PALUMBO M, MARCHI C, et al. Hdl metabolism and functions impacting on cell cholesterol homeostasis are specifically altered in patients with abdominal aortic aneurysm[J]. Front Immunol, 2022, 13: 935241. DOI: 10.3389/fimmu.2022.935241.
[41]	MILLER N E. Cetp inhibitors and cardiovascular disease: time to think again[J]. F1000Res, 2014, 3: 124. DOI: 10.12688/f1000research.4396.1.
[42]	KERSTEN S. Angptl3 as therapeutic target[J]. Curr Opin Lipidol, 2021, 32(6): 335-341. doi: 10.1097/MOL.0000000000000789
[43]	HARADA-SHIBA M, ALI S, GIPE D A, et al. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an angptl3 inhibitor, in healthy japanese and caucasian subjects[J]. Atherosclerosis, 2020, 314: 33-40. doi: 10.1016/j.atherosclerosis.2020.10.013